5M0B Stock Chart & Stats
€23.05
-€0.76(-4.50%)
At close: 4:00 PM EST
€23.05
-€0.76(-4.50%)
Day’s Range― - ―
52-Week Range€16.74 - €24.55
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.12B
Enterprise Value€50.31K
Total Cash (Recent Filing)€92.70M
Total Debt (Recent Filing)€1.46B
Price to Earnings (P/E)36.7
Beta0.60
Next Earnings
Nov 04, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding75,424,480
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.74
Price to Sales (P/S)1.29
P/FCF Ratio16.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€236.94M
Bulls Say, Bears Say
Bulls Say
Sustained Organic Revenue GrowthDouble‑digit organic growth across Healthcare and Diagnostics indicates durable end‑market demand and successful commercial execution. Recurring care relationships and repeat diagnostic testing support predictable revenue streams and provide a structural base for continued scale and margin expansion.
Margin Expansion And ROIC ImprovementSix consecutive quarters of margin improvement and a materially higher ROIC reflect sustainable operational leverage and successful integration of synergies. Improved profitability increases internal funding for growth, strengthens competitive positioning and enhances resilience to cost pressures.
Strong Cash Generation & LiquidityConsistently positive operating cash flow and rising free cash flow, alongside a larger committed RCF, provide durable financial flexibility. This supports capex for measured expansion, debt service and deleveraging, reducing execution risk on multi‑year targets while funding strategic options like India.
Bears Say
Elevated LeverageNet leverage near the 3x threshold constrains financial flexibility and raises vulnerability to rate shocks or cyclical downturns. Although leverage is falling, sustained elevated indebtedness limits capacity for large opportunistic M&A and increases refinancing and interest‑coverage sensitivity over the medium term.
India Start‑up Losses DilutiveRapid hospital roll‑out in India drives meaningful start‑up losses and capital consumption until utilization and payor mix mature. This creates a multi‑quarter drag on group margins and cash conversion, requiring patient capital allocation and clear ramp milestones to avoid long‑term dilution of returns.
Regulatory & Working‑Capital Risks In CEEMicro policy changes and tariff caps in key Central‑Eastern European markets, plus membership pruning in Romania, create structural revenue mix and cash‑collection risks. Longer public payer terms and working‑capital tie‑ups can persistently depress cash conversion and increase earnings volatility in core markets.
Medicover AB News
5M0B FAQ
What was Medicover AB’s price range in the past 12 months?
Medicover AB lowest stock price was €16.74 and its highest was €24.55 in the past 12 months.
What is Medicover AB’s market cap?
Medicover AB’s market cap is €3.12B.
When is Medicover AB’s upcoming earnings report date?
Medicover AB’s upcoming earnings report date is Nov 04, 2026 which is in 93 days.
How were Medicover AB’s earnings last quarter?
Medicover AB released its earnings results on Jul 22, 2026. The company reported €0.17 earnings per share for the quarter, beating the consensus estimate of €0.165 by €0.005.
Is Medicover AB overvalued?
According to Wall Street analysts Medicover AB’s price is currently Overvalued.
Does Medicover AB pay dividends?
Medicover AB does not currently pay dividends.
What is Medicover AB’s EPS estimate?
Medicover AB’s EPS estimate is 0.18.
How many shares outstanding does Medicover AB have?
Medicover AB has 75,424,480 shares outstanding.
What happened to Medicover AB’s price movement after its last earnings report?
Medicover AB reported an EPS of €0.17 in its last earnings report, beating expectations of €0.165. Following the earnings report the stock price went down -0.706%.
Which hedge fund is a major shareholder of Medicover AB?
Currently, no hedge funds are holding shares in DE:5M0B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicover AB
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.